芳香環轉化酵素抑制劑letrozole在子宮惡性腫瘤的檢視

The Role of Aromatase Inhibitor Letrozole for uterine Cancer

子宮惡性腫瘤的治療常為全子宮及輸卵管卵巢切除，淋巴結是否摘除則視情況而定。然患者有不宜手術者，或經化學治療、放射線治療、黃體素治療失敗者，或可採用芳香環轉化酵素抑制劑藥物治療，尤以letrozole療效較好、副作用較少。經文獻回顧，letrozole對子宮惡性腫瘤有不錯的效果，而雌激素接受器和黃體素接受器如為陽性者效果更為明顯，因此，在子宮惡性腫瘤的病理檢查時，宜同時檢測這些荷爾蒙接受器。 The treatment strategy for uterine cancer included total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadectomy. However, if the uterine lesion is difficult to resect surgically or failed chemotherapy, radiotherapy and progesterone therapy, an aromatase inhibitor as letrozole could be the drug of choice for treatment of patients, because its efficacy and minimal adverse effects. After reviewed the literature, there identified that the letrozole may be an effective for uterine cancer. Furthermore, routine estrogen receptors and progesterone receptors analyses could be useful to predict the response to hormonal therapy in uterine cancer.